Evotec SE
Company Profile
Business description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Contact
Essener Bogen 7
Manfred Eigen Campus
Hamburg22419
DEUT: +49 40560810
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
4,766
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,753.30 | 4.60 | -0.05% |
CAC 40 | 7,656.12 | 27.61 | -0.36% |
DAX 40 | 23,317.81 | 116.84 | -0.50% |
Dow JONES (US) | 42,171.66 | 44.14 | -0.10% |
FTSE 100 | 8,843.47 | 9.44 | 0.11% |
HKSE | 23,231.48 | 479.21 | -2.02% |
NASDAQ | 19,546.27 | 25.18 | 0.13% |
Nikkei 225 | 38,579.80 | 305.35 | -0.79% |
NZX 50 Index | 12,582.49 | 44.83 | -0.36% |
S&P 500 | 5,980.87 | 1.85 | -0.03% |
S&P/ASX 200 | 8,535.90 | 4.70 | 0.06% |
SSE Composite Index | 3,359.78 | 29.03 | -0.86% |